Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder

Neuropsychopharmacology

Volumn 17, Issue 1, 1997, Pages 1-11

  Meltzer, Herbert ^a   Bastani, Bijan ^b   Jayathilake, Karuna ^a   Maes, Michael ^a,c,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Clinical Research Center for Mental Health of Antwerp   (Belgium)

^d Stuivenberg General Hospital   (Belgium)

Author keywords

Cortisol; Depression; Fluoxetine; L 5 HTP; Obsessive compulsive disorder; Prolactin; Serotonin; Tricyclic antidepressants

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMITRIPTYLINE; DESIPRAMINE; FLUOXETINE; HYDROCORTISONE; IMIPRAMINE; NORTRIPTYLINE; PROLACTIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN RELEASE;

5-HYDROXYTRYPTOPHAN; ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG SYNERGISM; FEMALE; FLUOXETINE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PROLACTIN; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 0031010706     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00280-1     Document Type: Article

References (66)

1. Andersen IM, Cowen PJ (1986): Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Psychopharmacology 89:131-133
2. 1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely and chronically with citalopram. Naunyn-Schiedeberg's Arch Pharmacol 352:157-165
3. Artigas F, Perez V, Alvarez E (1994): Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatr 51:248-251
4. Bastani B, Nash JF, Meltzer HY (1990: Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatr 47:833-839
5. Beasley CM, Masica DN, Potvin JH (1992): Fluoxetine: A review of receptors and functional effects and their clinical implications. Psychopharmacology 107:1-10
6. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR (1989): Clomipramine in obsessive-compulsive disorder: Further evidence for a serotonergic mechanism of action. Arch Gen Psychiatr 46:23-28
7. Blier P, de Montigny C, Chaput Y (1988): Electrophysiological assessment of the effects of antidepressant treatments on the efficacy of 5-HT neurotransmission. Clin Neuropharmacol 11:1-10
8. Blier P, de Montigny G, Chaput Y (1990): A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatr 51:14-20
9. Briley M, Moret C (1993): Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16:387-400
10. Chaouloff F (1993): Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Rev 18:1-32
11. Chaput Y, de Montigny C, Blier P (1986): Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in rat brain. Naunyn-Schmiedebergs Arch Pharmacol 333:342-348
12. Chaput Y, De Montigney C, Blier P (1991): Pre- and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: An in vivo electrophysiological study in the rat. Neuropsychopharmacology 5:219-227
13. Charney DS, Heninger GR, Sternberg DE (1984): Serotonin function and mechanism of action of antidepressant treatment: Effects of amitriptyline and desipramine. Arch Gen Psychiatr 41:359-365
14. Charney DS, Goodman WK, Price LH, et al. (1988): Serotonin function in obsessive-compulsive disorder: A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy controls. Arch Gen Psychiatr 45:177-185
15. Cowen PJ, McCance SL, Cohen PR, Julier DL (1989): Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression. Psychopharmacology 99:230-232
16. Delgardo PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990: Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatr 47:411-418
17. Dumbrille-Ross A, Tang SW (1983): Manipulations of synaptic serotonine: Discrepancy of effects on serotonin S1 and S2 sites. Life Sci 32:2677-2684
18. Endicott J, Spitzer RL (1978): A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatr 35:837-844
19. Fuller RW (1992): The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 13:250-270
20. Fuller RW (1994): Minireview. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55:163-167
21. Fuller RW, Snoddy HD (1990: Serotonin receptor subtypes involved in the elevation of serum corticosterone concentrations in rats by direct- and indirect-acting serotonin agonists. Neuroendocrinology 52:206-211
22. Fuller RW, Snoddy HD, Molloy BB (1975): Potentiation of the L-5-hydroxytryptophan-induced elevation of plasma corticosterone levels in rats by a specific inhibitor of serotonin uptake. Res Comm Chem Pathol Pharmacol 10:193-196
23. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995): Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatr 52:53-60
24. Hall H, Sallemark M, Wedel I (1984): Acute effects of atypical antidepressants on various receptors in the brain. Acta Pharmacol Toxicol 54:379-384
25. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatr 23:56-61
26. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study. J Neurochem 60:776-779
27. Hjorth S, Carlsson A (1986): Is pindolol a mixed agonist-antagonist at a central serotonin (5-HT) receptors. Eur J Pharmacol 129:131-138
28. Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, German JM, Klein DF, Liebowitz MR (1991): Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder. Psychiatr Res 36:1-17
29. Hwang E, VanWoert M (1980): Acute versus chronic effects of serotonin uptake blockers on potentiation of the serotonin syndrome. Commun Psychopharmacol 4:161-176
30. Hwang E, Magnussen J, VanWoert M (1980): Effects of chronic fluoxetine administration on serotonin metabolism. Res Comm Chem Pathol Pharmacol 29:79-98
31. 3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology 55:336-343
32. Lahti RA, Barsuhn C (1980): The effect of antidepressants on L-5-HTP-induced changes in rat plasma corticosteroids. Res Comm Chem Pathol Pharmacol 28:343-349
33. 1A) receptor activation: Effects of 5-HT receptor and β-adrenoceptor antagonists. J Clin Endocrinol Metabol 70:670-674
34. 1A receptor responsivity in obsessive compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatr 48:540-547
35. Levy AD, Van der Kar LD (1992): Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants. Life Sci 51:83-94
36. 1A agonist, 8-OH-DPAT, in male rats. Brain Res 630:148-156
37. Lucey JV, O'Keane V, Butcher G, Clare AW, Dinan TG (1992): Cortisol and prolactin responses to D-fenfluramine in non-depressed patients with obsessive-compulsive disorder: A comparison with depressed and healthy controls. Br J Psychiatr 161:517-521
38. Maes M, Meltzer HYM (1995): The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds), Psychopharmacology, the Fourth Generation of Progress, New York, Raven pp 933-944
39. Maes M, De Ruyter M, Claes R, Bosma G, Suy E (1987): The cortisol responses to 5-hydroxytryptophan, orally, in depressive inpatients. J Affect Dis 13:23-30
40. Maes M, Blockx P, Vandewoude M, Schotte C, Martin M (1989a): Sex-linked differences in ACTH, cortisol and prolactin responses to 5-HTP in depressed patients and normal controls. Acta Psychiatr Scand 80:584-590
41. Maes M, Vandevelde R, Suy E (1989b): Influences on cortisol and noradrenergic turnover of healthy controls and depressed patients during L-tryptophan loading. J Affect Dis 17:173-182
42. Maes M, D'Hondt, P, Martin M, Claes M, Schotte C, Vandewoude M, Blockx P (1991): L-5-hydroxytryptophan stimulated cortisol escape from dexamethasone suppression in melancholic patients. Acta Psychiatr Scand 83:302-306
43. Maes M, D'Hondrt P, Meltzer HY, Cosyns P, Blockx P (1995): Effects of serotonin agonists on the negative feedback by glucocorticoids on the hypothalamic-pituitary-adrenal axis in depression. Psychoneuroendocrinology 20:149-167
44. Maes M, Vandoolaeghe E, Desnyder R (in press): Efficacy of treatment with trazodone in combination with pindolol and fluoxetine in major depression. J Affect Disord
45. Maj J, Moryl E (1993): Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol 3:85-94
46. Meltzer HY, Maes M (1994): Effects of pindolol and 5-HTP-induced prolactin and cortisol responses. Psychopharmacol 114:635-643
47. Meltzer HY, Simonovic M. Sturgeon RD, Fang VS (1981): Effect of antidepressants, lithium and electro-convulsive treatment on rat serum prolactin levels. Acta Psychiatr Scand 63:100-121
48. Meltzer HY, Wiita B, Tricou BJ, Simonovic M, Fang V, Manov G (1982): Effect of serotonin precursors and serotonin agonists on plasma hormone levels. In Ho B (ed), Serotonin in Biological Psychiatry, New York, Raven pp 117-138
49. Meltzer HY, Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R (1984): Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders: Enhanced response in depression and mania. Arch Gen Psychiatr 41:366-374
50. O'Keane V, O'Hanion M, Webb M, Dinan T (1991): D-fenfluramine/prolactin responses throughout the menstrual cycle: Evidence for an oestrogen-induced alteration. Clin Endocrinol 34:289-292
51. O'Keane V, McLoughlin D, Dinan TG (1992): D-fenfluramine-induced prolactin and cortisol release in major depression: Response to treatment. J Affect Dis 26:143-150
52. Peroutka SJ, Snyder SH (1980): Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88-90
53. Price LH, Charney DS, Delgado PL, et al. (1989): Effects of desipramine and fluvoxamine treatment of the prolactin response to tryptophan: Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatr 46:625-631
54. Shapira B, Reiss A, Kaiser N, Kindler S, Lerer B (1989): Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affect Dis 16:1-4
55. Shapira B, Cohen J, Newman ME, Lerer B (1992): Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biol Psychiatr 33:531-535
56. Stein DJ, Spandaccini E, Hollander E (1995): Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10:11-18
57. 3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behavior. Psychopharmacology 80:150-155
58. Wamsley JK, Byerley WF, McCabe RT, et al. (1987): Receptor alterations associated with serotonergic agents: An autoradiographic analysis. J Clin Psychiatr 48:19-25
59. 1A receptors in rat brain following antidepressant drug treatment. Synapse 4:347-352
60. Wilkinson LO, Dourish CT (1991): Serotonin and animal behavior. In: Peroutka SJ (ed), Serotonin Receptor Subtypes: Basic and Clinical Aspects, New York, Wiley-Liss, pp 147-210
61. Wong DT, Bymaster FP (1981): Subsensitivity of serotonin receptors after long-term treatment of rats with fluoxetine. Res Commun Chem Pathol Pharmacol 32:41-51
62. Wong DT, Reid LR, Bymaster FP, Threlkeld PG (1985): Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors. J Neural Transm 64:251-269
63. Wong DT, Threlkeld PG, Robertson DW (1991): Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 5:43-47
64. Wong DT, Bymaster FP, Engleman EA (1995): Minireview: Prozac (Fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 57:411-441
65. Yen TT, Wong DT, Bemis KG (1987): Reduction of food consumption and body weight of normal and obese mice by chronic treatment with fluoxetine: A serotonin reuptake inhibitor. Drug Dev Res 10:37-45
66. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987): Serotonergic activity in obsessive-compulsive disorder. Arch Gen Psychiatr 44:946-951